EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.21
-0.04 (-0.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.25
Open5.10
Bid5.10 x 900
Ask5.21 x 1300
Day's Range5.10 - 5.40
52 Week Range2.25 - 12.89
Volume18,148
Avg. Volume76,623
Market Cap24.105M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks Small Cap Research

    EYEG: Solid results – moving towards regulatory filings later this year

    By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is sticking to its business plan, despite any disruption from the pandemic. Meetings with regulators are on the schedule, and preparatory work for its approval filing continues. First quarter results were in-line with estimates. Research and development rose to $0.9 million in the quarter,

  • Zacks Small Cap Research

    EYEG: An Active 2020 with More to Come

    By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross-linked formulation of sodium hyaluronate (HA). 2019 was a turning point for EyeGate Pharmaceuticals. In March, 2019, the

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Fri., Nov. 22, 2019: TSLA, UBER, SPLK, EYEG, WKHS

    Benzinga Pro's Stocks To Watch For Friday Tesla (TSLA)  - Shares were down about 3% to under the $350 level following Thursday evening's  unveiling  of the company's new pickup, the Cybertruck.  Uber (UBER) ...

  • Zacks Small Cap Research

    EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch? OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020?

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT OBG-PRK: Pivotal Data Upcoming, 2020 Launch Feasible OBG-PE: Pre-Pivotal Study Moving Quick, Pivotal in 2020? We continue to be encouraged by the recent rapid and consistent progress of both the OBG-PRK and OBG-PR programs. The quick pace the ongoing studies follows speediness in nailing down clinical site, trial design and

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • Benzinga

    Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

    Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes. "We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From.

  • Zacks Small Cap Research

    EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT FDA Approves IDE for OBG-PRK Pivotal Study, Topline Results Expected Later This Year… The major recent news on the operating front was ...